1. Pink Sheet
  2. >>Agency Leadership

Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs

 
• By Jessica Merrill

Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”

Valeant Pharmaceuticals International Inc. is turning its back on CEO J. Michael Pearson, the man who built Valeant into a Wall Street darling through a strategy of acquisitions, cost cuts and price hikes. Now that elements of that strategy have backfired and the company’s stock price has fizzled like a sparkler in a downpour, the company announced March 21 that Pearson will be replaced by a successor yet to be named.

Valeant has begun the search for a new chief executive, who will be charged with turning around the troubled company, while Pearson will continue in the role and stay on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Could EU Collective Procurement Counter US Most Favored Nation Policy?

 
• By Francesca Bruce

Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.

EMA Says Digital Transformation A ‘Fundamental Shift’ In Meeting Regulatory Challenges

 
• By Eliza Slawther

Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.